key: cord-0746640-zk03ljns
authors: Deng, Zhifeng; Zhang, Minli; Zhu, Ting; Liu, Zhili; Liu, Zheming; Xiang, Rong; Zhang, Wei; Xu, Yu
title: Dynamic changes of peripheral blood lymphocytes subsets in adult patients with COVID-19
date: 2020-07-04
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2020.07.003
sha: ccd2cd6737088e95273ae5ffef75a13dc7bfb15b
doc_id: 746640
cord_uid: zk03ljns

Abstract Introduction Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been widely spread. We aim to investigate the dynamic changes of peripheral blood lymphocytes subsets in adult patients with COVID-19. Methods Electronic medical records including demographics, clinical manifestation, comorbidities, laboratory data, and radiological materials of 435 hospitalized COVID-19 patients, with confirmed result of SARS-CoV-2 viral infection, were extracted and retrospectively analyzed. The counts of lymphocyte subsets at each week after the onset of the illness were compared with other weeks of illness and with those from normal individuals. Results The various lymphocyte subsets (CD3 +, CD4 +, CD8 +, CD19 +and CD16/56 +) were below the normal ranges at the first week after the onset of the illness, reaching a nadir during the second week, which increased gradually in the third week and returned to normal levels in the fifth week, but was still lower than the healthy controls. The CD3+, CD4+ and CD8+ counts were significantly lower in those with severe disease compared to those with non-severe disease, and in those patients that died compared to those who recovered. Discussion our research indicates that the levels of peripheral blood lymphocyte subsets (CD3 +, CD4 +, and CD8 +) are associated with disease progression, severity, and prognosis in patients with COVID-19. Dynamic monitoring of human immune function is one of the indicators for evaluating the severity and prognosis of COVID-19 patients, and it is helpful to formulate appropriate treatment strategies.

. The new coronavirus has a long incubation period and is highly contagious [3] .

Patients with covid-19 has symptoms such as fever, dry cough, and fatigue in the early stage, and later easily develop into acute respiratory distress syndrome, respiratory failure, and shock, or combined failure of other organs seriously, or even death [2, 4] . By May 12th 2020, according to the government announcement, there are 82919 confirmed cases and 4633 deaths reported in China [5] .Through a series of preventive control and medical treatment measures , China's epidemic situation has been controlled to a certain extent, but the number of morbidities and deaths outside China has exceeded that of China and is on the rise. Therefore, COVID-19 is a major global health issue with high morbidity and mortality.

As we all know, lymphocytes are the main immune cells to eliminate the virus. In conventional viral infections, the proportion of lymphocytes in peripheral blood usually increases. However, peripheral lymphocytopenia was found in severe pandemic H1N1 influenza A and SARS [6, 7] . T lymphocytes play a key role in adaptive immunity against influenza a virus infection, which can reduce the severity of the symptoms during infection. The study found that the total number of lymphocytes, CD3+T cells, CD4+T cells and CD8+T cells decreased significantly in patients with influenza A/H1N1 in the acute phase [8] . Peripheral lymphocytopenia was also found in the sever patients with COVID -19 [1, 2, 4, 9] . The seventh edition of COVID -19 Diagnosis and Treatment Scheme issued by the National Health Commission of China [10] pointed out that the progressive decline of peripheral blood lymphocyte count and the continuous decline of CD4+T and CD8+T cells were one of the indicators that indicate the deterioration of the patient's J o u r n a l P r e -p r o o f condition. Although many clinical studies have reported peripheral lymphocytopenia in patients with COVID-19 in laboratory tests, the dynamic changes of peripheral blood lymphocyte subsets in patients with COVID-19 have rarely been reported. In this retrospective study, we aimed to observe the dynamic changes of peripheral blood lymphocyte subsets in patients with COVID-19.

Research objects and data collection Table 1 ). The patients with reverse transcriptase polymerase chain reaction (RT-PCR) for SARS-CoV-2 had turned negative at the sixth week, but still need oxygen or treatment for complications. week after the onset of the illness, reaching a nadir during the second week, which increased gradually in the third week and returned to normal levels in the fifth week, but was still lower than the healthy controls. There were significant decreases in the CD3+, CD4+, CD8+ counts over each of the six weeks of the COVID-19 illness compared to healthy controls. The CD16/56 + counts did not change statistically significant between weeks 3 and 4, weeks 5 and 6. The CD19 + counts did not change statistically significant except between weeks 2 and 3 (Table 2, Figure 1 ). Counts expressed as cells×10 6 /L±1 standard deviation. The lymphocyte subsets counts were compared between those patients with COVID-19 and those of normal individuals: Figure 2 ).

In 

Lymphocytosis has also been found in acute (severe measles [11] , SARS-COV [12] , Ebola virus [13] ) and chronic (HIV infection [14] ) viral infections, as well as in noncommunicable diseases (systemic lupus erythematosus [15] , cerebral hemorrhage [16] ). However, these We measured the changes of peripheral blood lymphocyte subsets in 435 patients with COVID-19 for at least 6 weeks. After analysis, we found that CD3+ and CD4 + decreased NK cells are an important component of the innate immunity system, they are the first line of defense against the invasion of exotic microorganisms. Before specific immune activation, innate immunity has been activated and plays an important role in resisting bacterial and viral infections [19] . CD16/56+ NK cells began to decrease in the first week, reaching its lowest point in the second week, and had returned to normal by

week 5. The data show that the CD16/56+ counts were higher in more severely ill patients in the first week, while CD16/56 + count in the severe patients was lower than that in non-severe patients in other time periods. Similar findings were found in between the J o u r n a l P r e -p r o o f recovery and death groups. The above hints showed that the innate immune function gradually decreased in the first week of symptom onset, the immune function decreased more rapidly in the severely ill patients and the death group, and the weakest innate immune function in the second week. Our research found that the level of T lymphocytes reached the lowest point in the second week, the body's cellular immune function was also the weakest, and the resistance was the worst. At this time, it may be prone to further aggravate viral infections or bacterial infections, which may be the key node of the disease course. But it needs further confirmation.

The reason for the decrease of peripheral blood lymphocytes may be due to the redistribution and migration of lymphocytes to the respiratory system to resist the virus, and Lymphocyte transport mediated by cytokines also plays a role in this process. Our study found that lymphocytes gradually decreased in the first and second weeks after the onset of illness, but from the third week, the lymphocyte counts gradually increased. It is possible that lymphocytes from the early circulation entered the inflammatory lung tissue, and lymphocytes from the inflammatory lung tissue reentered the circulation in the later period. Liu [20] et al reported that the T cell counts of the death groups remained at a low level. This study shown an increased in the T cell counts of the death groups during the weeks 4 and 5, but the T cell counts did not return to normal.

This change did not change the outcome of the patients, suggesting that the recovery of immune function in such patients was slow. During the treatment, proper use of hormones should be paid attention to and avoid complications leading to death, such as secondary infection, cerebral hemorrhage, organ failure, etc. A recent autopsy report [21] showed that J o u r n a l P r e -p r o o f the lung had more lymphocytic infiltrates in the death patients with COVID-19. The above results support the hypothesis of lymphocyte redistribution. The reason for the lymphocyte decrease may also be that the virus directly infects and destroys lymphocytes, or it may be related to the apoptosis of lymphocytes induced by viral infection [22, 23] .

There were some limitations in our study. On the one hand, it was a retrospective study and the sample is not big enough. On the other hand, the number of patients was not consistent in each time period and the lack of clinical data. There are several factors led to this result. Frist, patients in the early stage of symptom onset did not receive hospitalization.

Second, clinicians did not pay attention to cellular immunity. Third, the patient's discharge or death from hospital affected the collection of samples. Further research is needed to overcome these limitations. Nevertheless, the observation time of this study is long and the sample size at the key nodes is large, the variation trend of cellular immune function in the treatment of diseases is not affected by the above factors, which provided moderate and important illumination for this topic.

In summary, our research indicates that the levels of peripheral blood lymphocyte subsets (CD3 +, CD4 +, and CD8 +) are associated with disease progression, severity, and prognosis in patients with COVID-19. Dynamic monitoring of human immune function is one of the indicators for evaluating the severity and prognosis of COVID-19 patients, and it is helpful to formulate appropriate treatment strategies.

Conflicts of interest None.

J o u r n a l P r e -p r o o f

Clinical features of patients infected with 2019 novel coronavirus in Wuhan，China

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

World Health Organization. WHO Director-General's remarks at the media briefing on

Genomic characterization and epidemi ology of 2019 novel coronavirus: implications for virus origins and receptor binding

Diagnostic importance of relative lymphopenia as a marker of swine influenza (H1N1) in adults

Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets

Host Immune Response to Influenza A Virus Infection［J］

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

National Health Commission of the People , s Republic of China.COVID-19's diagnosis and treatment Plan

Functional and phenotypic changes in circulating lymphocytes from hospitalized Zambian children with measles

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study

Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains

Canadian Public Health Laboratory Network laboratory guidelines for the diagnosis of neurosyphilis in Canada. Can

T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients

Lymphocytopenia is an independent predictor of unfavorable functional outcome in spontaneous intracerebral hemorrhage

Dynamic changes of laboratory parameters and peripheral blood lymphocyte subsets in severe fever with thrombocytopenia syndrome patients

Peripheral T lymphocyte subset imbalances in children with enterovirus 71-induced hand, foot and mouth disease

Analysis of peripheral blood T cells and B cells and NK lymphocyte subsets in HIV-l-infected individuals

The clinical course and its correlated immune status in COVID-19 pneumonia

Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine, Available online 25

Base-line lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)

Phase I doseescalation and pharmacokinetic study of intravenous aflibercept in combination with docetaxel, cisplatin, and 5-fluorouracil in patients with advanced solid malignancies

Funding statement None.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.